Iraqi experience in the assessment of anti-Müllerian hormone utilization in clinical practice: An overview

Abstract

Abstract Anti-Müllerian hormone (AMH) is a dimeric glycoprotein, first recognized due to its action in male sex development. In women, it is synthesized by granulosa cells, pre-antral, and antral follicles; its main function in the ovary appears to be the inhibition of the early steps of folliculogenesis. Measurement of serum AMH made the assessment of ovarian reserve possible for more than 30 years. Its use has been expanded for many clinical implications, including assisted reproductive techniques, menopause, reproductive dysfunctions, the degree of ovarian damage/toxicity, and others. Numerous studies executed in this field concluded that AMH declines with aging; it has a positive correlation with oocyte yield in assisted reproduction; it is upregulated in polycystic ovarian syndrome and decreases in ovarian surgery and cancer therapy. This review aims to highlight the Iraqi experience in the implication of AMH assessment in clinical practice. We reviewed the PubMed database regarding the most recent literature in the assessment of AMH in Iraqi Clinical Practice; studies in polycystic ovarian syndrome (PCOS) patients were excluded. The review results show the importance of AMH assessment in many clinical fields especially for the evaluation of ovarian reserve of an infertile woman either to begin treatment strategists or follow-up patients and oncofertility counseling; yet studies must be encouraged in Iraq about it.